Neomorph
Updated: March 02, 2026
CEO - Philip Chamberlain
Country: USA | Funding: $109M (+)
Founded: 2020
Website: https://neomorph.com/
Neomorph develops "molecular glue" technology for binding drugs to tumor cell proteins and degrading these proteins to treat so far inaccessible targets. The company's degraders redirect cellular mechanisms known as E3 ubiquitin ligases to disease-causing proteins, leading to their degradation. This targeted protein degradation destroys the target protein by the 26S proteasome, thereby eliminating all associated biological activity. While heterobifunctional drugs still require a binding pocket on the target protein, "molecular glue" drugs bypass this requirement, thus offering a differentiated approach to drug development with different rules and the potential to target a broad spectrum of the proteome. The company is currently conducting clinical trials of its technology for the treatment of renal cell carcinoma.
Founded: 2020
Website: https://neomorph.com/
Neomorph develops "molecular glue" technology for binding drugs to tumor cell proteins and degrading these proteins to treat so far inaccessible targets. The company's degraders redirect cellular mechanisms known as E3 ubiquitin ligases to disease-causing proteins, leading to their degradation. This targeted protein degradation destroys the target protein by the 26S proteasome, thereby eliminating all associated biological activity. While heterobifunctional drugs still require a binding pocket on the target protein, "molecular glue" drugs bypass this requirement, thus offering a differentiated approach to drug development with different rules and the potential to target a broad spectrum of the proteome. The company is currently conducting clinical trials of its technology for the treatment of renal cell carcinoma.
